Evidence map›Paper›PMID 42675248›Full record

ArticleJournal of general internal medicine2026

Transgender Health and Cardiovascular Disease Risk: Future Directions for Research.

Roy Sistovaris, Timothy Lim, Arjee Javellana Restar, May Navarra, Sari Reisner, Carl G Streed

Abstract readEditorial
PubMed Publisher
In one paragraph

Article in Journal of general internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Roy SistovarisDepartment of Community Health Sciences, Boston University School of Public Health, Boston, MA, USA.
Timothy LimFaculty of Pharmacy, University of Toronto, Toronto, ON, Canada.
Arjee Javellana RestarDepartment of Social and Behavioral Sciences, Yale University, New Haven, CT, USA.
May NavarraGenderCare Center, Boston Medical Center, Boston, MA, USA.
Sari ReisnerDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA.
Carl G StreedGenderCare Center, Boston Medical Center, Boston, MA, USA. Carl.streed@bmc.org.ORCID http://orcid.org/0000-0003-3075-253X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The recent sociopolitical discourse has intensely scrutinized gender-affirming care for transgender people. Despite this attention, transgender health remains understudied, especially in the case of cardiovascular disease (CVD), the leading global cause of death. While hormones influence CVD risk, the mechanisms, directionality, and extent are inadequately characterized. While not all transgender people pursue hormone therapy, they have a greater risk of developing CVD than cisgender people, regardless of hormone use. More outcomes research is urgently needed to identify the biopsychosocial determinants of CVD in collaboration with transgender communities to improve their cardiovascular health and, potentially, the health of the general population.

Indexed as

cardiovasculartransgender

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.